A22.7 Anthrax sepsis

Name of the Condition

• Anthrax sepsis (ICD-10-CM Code: A22.7)

Summary

Anthrax sepsis is a severe, systemic bacterial infection caused by Bacillus anthracis that results in widespread inflammation and organ dysfunction. It occurs when the infection spreads from a localized site (e.g., skin, lungs, or gastrointestinal tract) into the bloodstream, leading to septic shock. Prompt medical intervention is critical to reduce mortality and prevent irreversible organ damage.

Causes

Anthrax sepsis is caused by the spore-forming bacterium Bacillus anthracis. Infection begins with exposure to spores through inhalation, ingestion, or skin contact, followed by bacterial proliferation and release of toxins. When the immune system fails to contain the infection, bacteria enter the bloodstream, triggering a systemic inflammatory response that leads to sepsis.

Risk Factors

• Untreated or advanced localized anthrax (e.g., cutaneous, pulmonary, or gastrointestinal forms).
• Delayed medical treatment after exposure to Bacillus anthracis.
• Weakened immune system (e.g., due to chronic illness, immunosuppressive therapy, or age).
• High bacterial load or virulent strain exposure.

Symptoms

• Fever, chills, and rapid heart rate (tachycardia).
• Low blood pressure (hypotension) and signs of shock (e.g., confusion, cool clammy skin).
• Multiple organ dysfunction (e.g., kidney failure, respiratory distress, or liver impairment).
• Skin manifestations (e.g., petechiae, purpura) or signs of the original infection site.

Diagnosis

Diagnosis involves clinical evaluation of sepsis criteria (e.g., SOFA or qSOFA scores) combined with laboratory tests. Blood cultures may detect Bacillus anthracis, though results can be delayed. Imaging (e.g., chest X-ray or CT) may reveal signs of the primary infection (e.g., inhalation anthrax). PCR or antigen tests can provide rapid confirmation. Documentation must link sepsis to anthrax exposure or prior infection.

Treatment Options

Treatment requires immediate intravenous antibiotics (e.g., ciprofloxacin, doxycycline) and supportive care (e.g., fluids, vasopressors for shock). Antitoxin therapy may be used to neutralize toxins. Source control (e.g., draining abscesses or removing infected tissue) is critical. Intensive care monitoring for organ support is often necessary.

Prognosis and Follow-Up

Prognosis depends on early treatment and organ involvement. Mortality remains high without prompt intervention. Survivors may require long-term monitoring for organ dysfunction or recurrence. Follow-up includes assessing organ recovery and managing complications (e.g., chronic fatigue or respiratory issues).

Complications

• Septic shock and multi-organ failure.
• Disseminated intravascular coagulation (DIC).
• Long-term organ damage (e.g., kidney or lung scarring).
• Secondary infections due to immune suppression.

Lifestyle & Prevention

• Avoid contact with infected animals or contaminated materials (e.g., hides, wool).
• Use protective equipment in high-risk occupations (e.g., veterinarians, lab workers).
• Ensure proper cooking of meat in endemic regions.
• Seek immediate care for unexplained fever or infection after potential exposure.

When to Seek Professional Help

Seek emergency care for sudden fever, chills, low blood pressure, or confusion after potential anthrax exposure. Prompt treatment is vital to prevent progression to sepsis. Individuals with a history of anthrax infection should monitor for systemic symptoms.

Tips for Medical Coders

Code A22.7 is assigned when sepsis is directly attributable to anthrax. Documentation must confirm the link between sepsis and Bacillus anthracis infection (e.g., positive cultures, clinical correlation). Do not code separately for localized anthrax unless explicitly documented as a distinct condition. Ensure sepsis criteria are met to support the diagnosis.